An intriguing observation was that AML patients with IDH mutations (either IDH1 or IDH2) showed high remission rates with an OS of 24.5 months and a composite complete remission CRc (CR + CRi) rate of 79% when treated with VEN-AZA (17). This evidence concerns the gene IDH1 and acute myeloid leukemia.